

江苏省首届青年学术年会

# 论文集

(医科分册)

JIANQSU  
1992

江苏省首届青年学术年会执行委员会编

中国科学技术出版社


江苏省首届青年学术年会

# 论文集

(医科分册)

江苏省首届青年学术年会

执行委员会编



JIANGSU  
1992

中国科学技术出版社

## 内 容 提 要

江苏省首届青年学术年会论文集（医学分册）共收录了有较高学术水平的论文 73 篇、论文摘要 30 篇，内容涉及基础医学的免疫学、遗传学、生理学、生物化学、病理学、寄生虫学等；临床医学的内科、外科、妇科、儿科、传染病、耳鼻喉科、眼科、护理；预防医学的营养卫生、食品卫生等；药学及中医中药的有关学科。这些论文集中反映了近几年江苏青年医学科技工作者的研究成果，对医学基础、临床、科研和教学工作均有参考价值。

（京）新登字 175 号

### 江苏省首届青年学术年会论文集

（医 科 分 册）

江苏省首届青年学术年会

执行委员会 编

\*

中国科学技术出版社出版发行（北京海淀区白石桥路 32 号）

江苏省新华印刷厂印刷

\*

开本：787×1092 毫米 1/16 印张：119 字数：2800 千字

1992 年 12 月第一版 1992 年 12 月第一次印刷

印数：1—1000 册 全套定价：134.00 元

ISBN 7-5046-0932-3/Z·88

## 江苏省首届青年学术年会 指导委员会名单

主    席：吴锡军  
副 主 席：孙钟秀  潘  恕  
秘 书 长：王世璜  
副秘书长：李茂典  
委    员：李庆逵  严  恺  钱钟韩  冯  端  窦国仁  
          童  傅  韦  钰  高亮之  余之祥  陈家伟  
          郭克礼  葛锁网  王永顺  潘宗白  陈  懿  
          何立权  王臻中  叶钟音  陈荣华

## 江苏省首届青年学术年会 执行委员会名单

主    席：尤肖虎  
副 主 席：张  荣  
秘 书 长：张铁恒  
副秘书长：王安宁  
委    员：王兆球  王建国  沈其荣  王心如  李剑波  
          梁德旺  毛罕平  姚  远  刘  平  钱海鑫  
          顾晓松  郭  荣  葛世荣  裘  伟  王明秋  
          杨善德  朱永官

## 前 言

当今时代，科学技术已成为决定生产力的首要因素，社会经济的发展更多地依赖于科学技术的进步，依赖于掌握先进科学技术的人。青年科技工作者作为跨世纪的科技生力军，必将并且正在成为我国科技队伍的骨干力量。有计划地培养和造就一支强大的、高水平的青年科技中坚力量，是一项重要的战略任务。江苏省科学技术协会主办的江苏省首届青年学术年会，旨在检阅江苏省青年科技工作者的科技成果，发现和培养优秀青年科技人才，推动全社会进一步形成关心、重视青年科技人才成长的良好环境，激励广大青年科技工作者奋发图强、建功立业。

本届年会的征文工作得到全省青年科技工作者以及海外留学生的大力支持，共收到应征论文 2000 余篇，其中来自美国、日本、英国、法国、加拿大、德国、菲律宾等国家的论文 20 余篇，内容涉及了理、工、农、医、交叉等学科领域，作者大部分为具有高、中级职称或博士、硕士学位的青年科技工作者，反映了江苏省乃至全国青年科技工作者的科技水平。应征论文经年会所聘请的专家委员会反复筛选，从中精选出 320 余篇，分理、工、农、医、交叉学科五部分汇编成论文集出版发行。由于论文集篇幅所限，许多优秀论文只好割爱。

本届年会得到了中共江苏省委、江苏省人民政府及有关部门的高度重视，得到了江苏省省级学会、各市人民政府、各市科学技术协会及所属学会、各高等院校、研究院所及有关单位的大力支持，特别是得益于南京大学、东南大学、南京农业大学、南京医学院、南京师范大学的积极协助和具体承办。论文集出版过程中承蒙中国科学技术出版社、江苏省新华印刷厂全力支持，并且有一大批热心的同志付出了辛勤劳动，籍此机会一并表示诚挚的谢意。

本书为江苏省首届青年学术年会论文集的医学分册，是在江苏省、市医学会、高等医药院校、解放军医疗卫生单位等初审推荐的 518 篇论文基础上，由专家评审委员会选出的 73 篇优秀论文、30 篇摘要汇编

而成。内容围绕国家卫生工作重点及江苏省医学科研攻关项目，追踪世界医学科技发展新动向，侧重与国民经济密切相关的医药保健及有关基础研究领域，注重医学的综合性和专题性、宏观和微观、理论和实践，体现了江苏省青年医学科技工作者的科学精神和学术水平。参加医学专家评审委员会的成员有王敬良、周志耀、黎介寿、杜竞辉、熊宗璠、杨玉、王廷芳、陈解民、单祥年、姚堃、陈德华、贾辅忠、黄志勇、王毓三、谈瑗声等先生，我们在此表示衷心感谢。

本分册的编辑工作由江苏省首届青年学术年会执行委员会医科分部的王心如、王虹、朱昌亮、沈建、黄煌、魏鹏等同志集体完成。印刷出版工作得到胡晓河、刘福在、禹正瑜等同志协助。由于时间仓促及编辑水平有限，难免会出现错误，希望读者予以谅解。

江苏省首届青年学术年会执行委员会医科分部

1992年10月22日

# 目 录

抗 IL-6 单抗治疗中出现大量 IL-6 免疫复合物 的积聚——一种细胞因子体内生成定量法 (High Amounts of -Circulating IL-6 in the Form of Monomeric Immune Complexes during Anti-IL-6 Therapy Towards a New Methodology for Measuring Overall Cytokine Production in Human in Vivo)	陆肇阳等(Lu Zhaoyang, et al.)(1)
同位素标记的单抗在检测血栓性疾病患者血浆 GMP-140 含量中的应用 (Detection of Plasma $\alpha$ -Granule Membrane Protein (GMP-140) using Radiolabeled Monoclonal Antibodies in Thrombotic Diseases)	吴国新等(Wu Guoxin, et al.)(8)
轮状病毒细胞培养的若干研究	孟继鸿等(14)
人心脏酸性铁蛋白放射免疫分析	金 坚等(19)
GB1。基因 17 号外显子内 C→T 突变导致 I 型血 小板无力症	顾建明等(22)
人浆细胞/多发性骨髓瘤细胞单抗 SI <sub>1</sub> 的产生及特征初步 分析	张 毅等(28)
生前及死后损伤中血小板反应的免疫组化定位	顾晓生等(33)
无脉络膜症家系的遗传学分析	倪 黎等(40)
单克隆抗体 NP28-5B 抗病(日本血吸虫病)免 疫的研究	曹建平(45)
钙通道拮抗剂对大鼠海马缺血磷脂酰肌醇代谢的影响	卢步峰等(50)
人肺腺癌细胞株 A549 细胞脂加氧酶的研究	徐 红等(55)
银耳孢糖对受照射荷瘤小鼠免疫功能保护作用的研究	郑仕中等(60)
扩张型心肌病心脏 HLA-Ⅰ 类抗原的异位表达及其 意义	李运有等(64)
二尖瓣狭窄肺循环血液动力学研究	张启高等(69)
英卡胺和心律平治疗室性心律失常的临床比较研究	单其俊等(73)
IL-6 对人肾脏系膜细胞 c-myc 原癌基因表达 的影响以及大黄的拮抗作用	刘志红等(77)
肾炎宁治疗系膜增殖性肾炎初步疗效观察	俞雨生等(82)
曲尼司特对豚鼠肺组织 $\beta$ 受体向下调节的影响	杨 明等(86)
PCR 技术快速检测结核性脑膜炎患者脑脊液中的结 核分枝杆菌的研究	宋 勇等(91)
咖啡因对膈肌收缩力及膈肌疲劳的影响	童茂荣等(95)
加压素受体拮抗剂对缺血性脑损伤保护作用研究	刘新峰(103)

人原发性肝癌及癌旁组织丙肝病毒基因及其抗体的研究.....	查文章等(107)
葡聚糖微球肝栓塞治疗肝癌疗效的病理学评估.....	王 杰等(112)
休克肝及再灌注后肝组织中氧自由基的直接测定及其意义.....	徐顺福等(116)
髓系单克隆抗体临床应用的研究.....	甘 毅等(121)
红细胞内铁含量的测定及其临床意义.....	徐开林等(127)
葡萄糖对伴和不伴高脂血清培养的兔主动脉平滑肌细 胞结构的影响.....	沈 捷等(131)
急性肾炎患儿中性白细胞趋化功能的观察.....	王晓燕等(137)
人乳吞噬细胞与金黄色葡萄球菌、大肠杆菌、绿脓杆 菌的相互作用.....	殷曙东等(141)
DNA 聚合酶链反应检测畸型儿心肌组织中弓形虫的研究 .....	石群立等(145)
心肌灌注门控断层显像初步研究.....	朱 虹等(148)
抗 TG 独特型抗体对 B 淋巴细胞抗体分泌功能的调节 .....	杨程德等(154)
自身免疫病患者抗钙调素自身抗体的研究.....	李晓军等(158)
Pirarubicin 联合碘油肝动脉内灌注处理兔 VX2 瘤 (Intra-hepatic arterial Chemotherapy Using Pirarubicin (TNP-Adriamycin) combined with Lipiodol in Rabbits with VX2 Tumors ) .....	赵中辛(Zhongxin ZHAO)(164)
门脉高压时胃粘膜病变发生机制的实验研究.....	穆 毅等(173)
重症胰腺炎营养支持方法的改进和疗效观察.....	任建安等(178)
多器官衰竭代谢支持的实验研究.....	全竹富等(183)
人胸腺上皮细胞及核超微形态定量分析.....	胡小南等(189)
雷公藤多甙联合小剂量环孢素 A 抑制猪小肠移植排 斥反应.....	廖彩仙等(194)
实验性脑水肿的 MRI .....	赵春生(200)
联合应用 LAK 细胞及 IL-2 治疗恶性脑肿瘤的临 床研究.....	潘蔚然等(206)
新生儿和婴幼儿手术创伤后内分泌——代谢反应的研究.....	汪 健等(209)
无出血性脑手术的动物实验研究.....	刘卫东等(214)
局部应用环孢素 A 对兔眼角膜的毒性研究 .....	黄振平等(222)
抗子宫内膜抗体在子宫内膜异位症诊断中的评价.....	刘 琦等(227)
宫颈根治术保护盆丛促进术后排尿功能恢复的 临床意义.....	霍汝娟等(231)
胎盘血流量下降对大鼠胎仔生长发育和胎盘结构的影响.....	吴元赭等(235)
农村妇女放置四种宫内节育器的六年随访结果.....	李 瑛等(241)
内淋巴囊局部免疫诱发自身免疫性感觉神经性聋的实 验研究.....	谭长强等(247)
一种用于喉部疾病语音诊断的新的声带模型.....	程启明(254)
X 线头影自动化诊断及模拟矫治疗效预测的计算机应	



用研究.....	赵春洋等(261)
辐照猪皮在深度烧伤创面的临床应用研究.....	朱 云等(265)
创伤后机体激素和代谢变化与代谢支持的影响.....	尹 路等(268)
糖尿病病人胰岛素剂量调整的计算机模拟.....	王 华等(273)
口腔粘膜给药系统 I: 头孢氨苄口腔粘膜粘附片的研究 .....	陈庆才等(279)
人外周血灰黄层细胞制备 $\alpha$ 干扰素和白细胞介素 2 的 联产工艺.....	刘 浦等(285)
洛美沙星片剂的研制及药物动力学.....	刁 勇等(288)
梨大食心虫性信息素的化学结构测定.....	孔繁蕾等(291)
偏最小二乘法(PLS)测定氧氟沙星尿药浓度及人 体内药物动力学研究.....	周国华等(295)
动物“内关”与其它途径注射硫酸阿托品的药理及毒 性作用比较.....	丁 斐等(300)
氟戊菊酯致肺损伤的生化效应研究.....	田海林等(304)
不完全交叉分组资料 Logistic 模型参数估计 的 EM 算法 .....	孙晓武等(309)
接触对苯二甲酸工人生物学监测指标的研究.....	邱 清等(313)
S <sub>2</sub> 蚊香烟雾对小鼠细胞 DNA 合成的影响 .....	唐 萌等(318)
逐步回归在评价和预测地面水水质中的应用.....	周建伟等(321)
降低香烟烟雾中致癌和高毒物质含量的新烟滤嘴材料 的研究.....	肖 杭等(326)
急性吸入原油蒸气对肝及血浆游离氨基酸水平的影响.....	胡迎青(330)
肾虚肝郁不孕症患者人格结构的研究.....	姚石安(335)
主观性耳鸣客观测量与中医临床证型关系探讨.....	王东方(339)
耳穴埋针对肥胖合并高脂血症血清脂质的调整作用.....	马小平(342)
机械通气治疗中并发症的观察和护理.....	宋燕波等(347)
临终病人的心理护理.....	缪亚萍(351)
运用 APIE 程序带教护理本科实习生的探讨 .....	胡 容等(354)

## 摘 要 部 分

### 胆盐引起腹泻的细胞分子机理

.....	黄旭培等(XP Huang , et al )(357)
ApoAI 基因的多态性与 NIDDM 关系的研究 .....	马向华(358)
甲型肝炎病毒感染后各感染标记的检测及其意义.....	潘秀珍等(359)
先天性心脏病心肌超微结构与临床对比观察.....	郑晓刚等(360)
脑缺血与再灌注对脑电图及其钙调素依赖性蛋白激酶 I 活性变化的研究.....	唐放鸣等(361)
SLE 患者 T 淋巴细胞 IL-2R 和血清 sIL-2R	

水平变化的研究·····	杨惠斌等(362)
越冬淡色库蚊生态生理学研究·····	苏天运等(363)
鼠体内卫氏并殖吸虫滞育虫体 MDH 同工酶谱的研究·····	俞小棕等(364)
丁胺卡那霉素对位听器毒性损伤的实验形态学研究·····	吕力为等(365)
瘤细胞成分在诱生巨噬细胞分泌肿瘤坏死因子- $\alpha$ 中的作用·····	胡玉香等(366)
4 种抗原用于斑点免疫金银染色试验诊断日本血吸虫病的比较·····	郑葵阳等(367)
胃网膜右动脉与冠状动脉吻合的新术式探讨·····	吴洪海等(368)
空肠与人造幽门代胃的抗反流作用·····	胡建华等(369)
75 例流行性出血热死因分析·····	史建科等(370)
经内窥镜食管腔内冷冻治疗食道贲门癌初步报告·····	许林等(371)
乙二胺四乙酸根面处理的扫描电镜研究·····	孙卫斌等(372)
Ebstein 心脏畸形的外科治疗·····	李小波(373)
脑膜瘤的瘤周水肿·····	杭春华等(374)
新生儿疾病血清自由基变化·····	郑大同等(375)
自由基清除剂和钙拮抗剂在实验性肝纤维化中的预防和保护作用·····	施瑞华(376)
163 例 IgM 肾病的临床病理联系及临床资料分析·····	蒋炜等(377)
雷公藤多甙治疗肾病的抗氧化机制——抑制中性粒细胞和系膜细胞产生活性氧·····	胡明昌等(378)
卡托普利对阿霉素心肌病的保护作用·····	卞劲松等(379)
癫痫患者血清和唾液中游离苯妥英钠浓度测定的临床意义·····	蔡卫民等(380)
ELISA 法测定尿液微量转铁蛋白及其对糖尿病肾病早期诊断的价值·····	吴惠毅等(381)
头胸导联与 Wilson 导联诊断右室梗塞的观察分析·····	王巍冬等(382)
加味温胆汤治疗慢性肾功能衰竭 70 例临床观察·····	严志林(383)
补肾疏郁法治黄体不健不孕 46 例·····	李丹(384)
卡那霉素对豚鼠耳蜗组织超氧化物歧化酶的影响·····	余万东等(385)
老年急性心肌梗塞的临床特点·····	钟宜干(386)

# 抗 IL-6 单抗治疗中出现大量 IL-6 免疫复合物的 积聚——一种细胞因子体内生成定量法

陆肇阳<sup>①</sup> Bataille R. Klein B.

(Plateau technique du CHR, BP1005, quai Moucousu, 44035 Nantes, France)

Brochier J.

(INSERM U291, 99 Rue Puech Villa, 34100 Montpellier, France)

Wijdenes J.

(Centre Regional de Transfusion sanguine, 25020 Besancon, France)

Brailly I.

(Immunotech, Luminy Case 915, 13288 Marseilles Cedex 9, France)

**摘要** 我们曾报导用抗 IL-6 单抗治疗浆细胞白血病,在治疗末期,病人体内出现大量能刺激 B9 杂交瘤增殖的活性(B9-SA)。本文采用凝胶过滤及亲和层析等方法研究了该 B9-SA。结果表明,进入体内的抗 IL-6 单抗阻断了 IL-6 与其靶细胞膜受体的结合,同时由于 IL-6/抗 IL-6 单价免疫复合物的形成妨碍了肾脏对 IL-6 的排泄,最终导致大量 IL-6 复合物在循环中积聚。由于肿瘤细胞中对细胞因子敏感的亚克隆被选择性地扩增,从而给病人带来新的潜在危险。因此,我们认为单用一种抗细胞因子单抗治疗某些疾病时应慎重。我们还首次推导了一个测定体内 IL-6 日生成量的数学模型(该病人 IL-6 的日生成量约为 15 $\mu$ g)。本结果对细胞因子的临床应用具有重要意义。

## 1 Introduction

We, and others, have shown that IL-6 is a major myeloma-cell growth factor in patients with active disease, especially in patients with terminal disease<sup>[1,2]</sup>. These observations led us to make a clinical trial with anti-IL-6 monoclonal antibodies (mAb) in a patient with terminal disease; it resulted in a complete blockage of myeloma-cell proliferation for one-and half month in vivo<sup>[2]</sup>. In addition, the production of C reactive protein (CRP), an acute-phase protein whose production by human hepatocytes is totally controlled by IL-6 in vitro<sup>[3]</sup>, was completely inhibited. At the end of the anti-IL-6 treatment, high levels of an activity stimulating the proliferation of the B9 hybridoma was detected<sup>[2]</sup>. The present study was designed to explore the mechanisms responsible for this phenomenon.

## 2 Materials and methods

<sup>①</sup> 苏州医学院

One patient with secondary plasma-cell leukemia was treated with anti-IL-6 mAb. The patient was treated for two months, first with the anti-IL-6 B-E4 mAb for 6 days and subsequently with the anti-IL-6 B-E8 mAb until day 67 following the beginning of treatment. On day 82, the patient received a new chemotherapy regimen.

The anti-IL-6 mAb (B-E4, IgG2b and B-E8, IgG1) were prepared by J. Wijdenes by immunizing mice with recombinant IL-6<sup>[4]</sup>. The two mAb recognize different epitopes on the IL-6 molecule and the B-E8 mAb was about five times more potent than the B-E4 mAb in inhibiting the biological activity of IL-6<sup>[4]</sup>.

5,000 B9 cells<sup>[5]</sup> were cultured with serial dilutions of the sample in 96-well, flat-bottomed culture dishes in 100  $\mu$ l of RPMI 1640 culture medium containing 5% FCS. After an incubation period of three days at 37 in 5% CO<sub>2</sub>, the cells were exposed to MTT (Sigma, St Louis, MO) for 4 hours at 37<sup>[6]</sup>. One Unit of B9-stimulating activity (B9-SA) is defined as the amount inducing half-maximal optical densities and corresponds to approximately 5 pg of recombinant IL-6.

#### Affinity chromatography

For the protein A-Sepharose column, the samples were run with 50 mM PBS, pH 8.1. The bound material was eluted with 0.1 M glycine-HCl, pH 2.4. For the other columns, the washing and eluting buffers were 50 mM PBS, pH 7.2, and 0.1 M glycine-HCl, pH 2.3, respectively. Each fraction was immediately neutralized with 1 M NaHCO<sub>3</sub> and was then assayed for B9-SA at different dilutions.

A 4 ml sample was loaded onto a Sephadex G-200 column (100 cm x 2.6 cm) and was chromatographed at 4°C with 50 mM PBS (pH 7.2) as eluting buffer. To dissociate expected immune complexes, the samples were dialyzed for 12 hours with a 0.1 M glycine-HCl buffer (pH 2.3) and were subsequently gel filtrated with the same acid buffer. Each fraction was neutralized with 1 M NaHCO<sub>3</sub> and assayed for B9-SA at different concentrations.

#### Mathematical procedure for determining the whole daily production of IL-6

The in vivo situation is modeled by a system comprising two compartments, as illustrated in Figure 1. For the anti-IL-6 mAb compartment, let  $y^+$  = the influx of anti-IL-6 mAb resulting from the daily injection of mAb;  $y_1^-$  = the efflux of free mAb;  $y_2^-$  = the efflux of IL-6-bound mAb;  $mAb_1$  = the serum concentration of free mAb;  $mAb_2$  = the serum concentration of IL-6-bound mAb;  $mAb/day$  = the amount of daily injected mAb;  $V$  = plasma volume. Under steady state conditions (hypothesis 1);  $y^+ = y_1^- + y_2^-$  (equation 1),  $mAb_1$  and  $mAb_2$  are constant, and  $mAb/day = V \int_0^{1day} y^+ dt$ .

In addition, the influx and efflux of mAb can be expressed as;  $y_1^- = k_1 mAb_1$  and  $y_2^- = k_2 mAb_2$  where  $k_1$  and  $k_2$  are constant. In the case of monomeric immune complexes (hypothesis 2), the clearance of these complexes is similar to that of the free mAb<sup>[7]</sup>, and then  $k_1 = k_2$ . This hypothesis is verified for the B-E8 mAb<sup>[4]</sup> and the present study).  $y_2^- = y^+ + mAb_2 / (mAb_2 + mAb_1)$  (equation 2). Concerning the IL-6 compartment, let  $x^+$  = the influx of circulating IL-6 due to the production of IL-6,  $x^-$  = the efflux of circulation IL-6 in the form of immune complexes,  $[IL-6]$  = serum concentration

of IL-6, and  $\text{IL-6/day} = \text{daily production of IL-6}$ . Thus  $\text{IL-6/day} = V \int_0^{1\text{day}} x^+ dt$ . In the present study, the anti-IL-6 mAb was injected in sufficient amounts to completely block the binding of IL-6 by the cell surface receptor as well as its renal elimination. By assuming that there is no other route of elimination of IL-6 than in the form of immune complexes (hypothesis 3) and in case of steady state conditions (hypothesis 1);  $x^+ = x^- = y_2^-$ . Thus,  $\text{IL-6/day} = V \int_0^{1\text{day}} x^+ dt = V \int_0^{1\text{day}} x^- dt = V \int_0^{1\text{day}} y_2^- dt$ . This equation combined with equation 2 gives;  $\text{IL-6/day} = V \int_0^{1\text{day}} y^+ dt \frac{mAb_2}{(mAb_2 + mAb_1)}$ , or  $\text{IL-6/day} = (mAb/\text{day}) \frac{mAb_2}{(mAb_1 + mAb_2)}$ . In the present study,  $mAb_1 + mAb_2 = \text{total concentration of mAb}$ . In addition, as all the circulating IL-6 is bound to the anti-IL-6 mAb (as demonstrated in the following), one have  $[\text{IL-6}] = mAb_2$ . Thus,  $\text{IL-6/day} = (mAb/\text{day}) \frac{[\text{IL-6}]}{[\text{mAb}]}$

### 3 Results

#### 3.1 Serum levels of B9-stimulating activity (B9-SA) in the patient treated with anti IL-6 mAb

No serum B9-SA was found prior to treatment. After injections of the anti-IL-6 B-E4 mAb, high serum B9-SA levels were found and lasted for 6 days (Figure 1). This activity was completely neutralized by the two different anti-IL-6 mAb which recognize different epitopes on the IL-6 molecule (Figure 2). No serum B9-SA could be detected throughout the treatment with the B-E8 mAb<sup>[4]</sup>. When the injection of B-E8 was stopped, very high serum B9-SA was detected again, especially on day 80, when no more circulating anti IL-6 mAb could be detected (<sup>[2]</sup> and Figure 2).

#### 3.2 Evidence that the B9-SA present in day-80 and day-4 sera is IL-6 bound to the anti-IL-6 mAb

All the B9-SA present in the day-80 serum of the patient was retained on a protein A-sepharose column. After gel filtration on a Sephadex G-200 column, all the B9-SA present in the day-80 serum eluted in a peak of 185,000 MW whereas natural IL-6, eluted in a 25,000 MW peak. When the day-80 serum was treated with a pH2.3 buffer and was chromatographed at the same pH, all the B9-SA eluted in a 25,000 MW peak similar to natural IL-6. These experiments indicated that the B9-SA present in the day-80 serum was IL-6 bound to an immunoglobulin molecule. Since no more anti-IL-6 mAb could be detected in this serum, we investigated whether the immunoglobulin molecule bound to IL-6 was a human or mouse immunoglobulin. It was found that all the B9-SA contained in the day-80 serum was retained on anti-mouse IgG-sepharose. This clearly indicated that the IL-6 molecules contained in the day-80 serum were bound to residual murine anti-IL-6 B-E8 mAb, which were in too low a concentration to be detected by ELISA (Figure 1). Similar results (not shown) were obtained for the B9-SA present in the day-4 serum.

#### 3.3 IL-6 accumulated in the form of immune complexes throughout the anti-IL-6 treatment

Whereas no B9-SA was found in the day-26, day-40, day-60 sera of the patient (Figure 1), significant B9-SA could be detected after acid treatment and gel filtration of these sera. Furthermore, this B9-SA also eluted in a 25,000 MW peak. No IL-6 activity could be detected after gel filtration at pH 2.3 of the patient's serum before anti-IL-6 treatment (results not shown). The titration of the IL-

6 activity in the different fractions obtained after gel filtration at acid pH made it possible to estimate the total IL-6 activity bound to the circulating mAb in these different sera (Table 1). An approximate 50% loss of IL-6 activity due to acid treatment was also found in the day-80 patient serum.

**Table 1 Estimation of the daily production of IL-6 in the patient treated with anti-IL-6 mAb**

Days after beginning the treatment	4	40	60	80
Concentration of anti-IL-6 mAb( $\mu$ g/ml)	45 <sup>(1)</sup>	7.5 <sup>(2)</sup>	10 <sup>(2)</sup>	ND <sup>(3)</sup>
Serum IL-6 activity bound to anti-IL-6 mAb (U/ml) <sup>(4)</sup>	624	960	1150	1020
Corrected serum IL-6 activity (U/ml) <sup>(5)</sup>	1248	1920	2300	2040
Serum concentration of IL-6 (ng/ml) <sup>(5,6)</sup>	7.43	11.43	13.63	12.14
Ratio of IL-6 bound mAb to free mAb( $\times 1000$ ) <sup>(7)</sup>	0.55	4.9	4.4	NE <sup>(8)</sup>
Daily injection of anti-IL-6 mAb (mg)	40 <sup>(1)</sup>	10	10	0
Daily production of IL-6 ( $\mu$ g)	NE <sup>(8)</sup>	15.2	13.6	NE <sup>(8)</sup>

1 B-E4 mAb; 2 B-E8mAb; 3 ND=not detectable;

4 The serum IL-6 activity was determined following gel filtration at pH 2.3;

5 The serum IL-6 activity was multiplied by 2, since the loss of IL-6 activity due to gel filtration was estimated to be about 50%;

6 we determined that 1 U of IL-6 activity in the B9 hybridoma assay corresponded to 5 pg of rh-IL-6 (MW 21,000). It thus corresponded to  $5 \times (25,000/21,000)$  pg of natural IL-6 since the natural serum IL-6 was found to have a 25,000 MW.

7 The MW of the two anti-IL-6 mAbs was 160,000 and we considered that one anti-IL-6 mAb molecule has two potential IL-6 binding sites.

8 NE; non-valuable.

### 3.4 Estimation of the total daily production of IL-6

Indeed treatments at pH 2.3 and gel filtration allowed measurements of IL-6 activity, bound to the anti IL-6 mAb, to be made and, in consequence, allowed us to determine the ratio of IL-6-bound mAb to free mAb in these sera (see detailed explanations in Table 1). This made it possible to establish a minimal estimate of the daily production of IL-6 in the patients, according to the mathematical procedure detailed in the "Materials and Methods" section. One of the necessary three assumptions was that the system was in steady state. This assumption was verified for the day-40 and day-60 sera since a constant amount of anti-IL-6 mAb was injected daily and a stable serum mAb concentration was reached. It was not verified for the day-4 and day-80 sera (<sup>[12]</sup> and Table 1). In consequence, the estimate was made only for the day-40 and day-60 sera; it ranged around 15  $\mu$ g of IL-6 per day (Table 1).

## 4. Discussion

Recombinant IL-6 has also a half-life of few minutes in the serum and ,similar to IL-2<sup>[8]</sup>, is mainly bound by cell surface receptors (primarily in the liver )and is also eliminated by renal filtration<sup>[9]</sup>.

IL-6 is overproduced in patients with active MM. In the patient with terminal MM who was treated by anti-IL-6 mAb, the efficacy of the mAb in preventing IL-6 binding to its receptor in vivo was demonstrated by the complete inhibition of CRP production and by the blockage of myeloma-cell proliferation<sup>[2]</sup>. This study shows that IL-6 accumulated in the plasma of this patient in the form of monomeric immune complexes (i. e: 185 kDa MW) as a consequence of this non-absorption by IL-6 receptors. Moreover, the formation of these monomeric immune complexes stopped IL-6 from being eliminated by renal filtration.

This finding is of general interest for the in-vivo use of cytokinebinding molecules, especially in cancer patients. The technique may represent a potential danger by mobilizing high levels of cytokine, in the form of complexes, close to tumoral subclones hypersensitive to the cytokine, and which, unlike normal cells, may be able to dissociate these complexes. This is all the more evident in the case of monomeric immune complexes which should have a long half-life in vivo similar to that of the free B-E8 mAb (3-4 days)<sup>[2]</sup>, predicted by data of the literature<sup>[7]</sup>, and as directly demonstrated by one of us by studying pharmacokinetic of radiolabeled IL-6 in animals pretreated with the B-E4 or B-E8 mAb (H. Brailly, unpublished observations). This may explain why the patient became resistant to the 2-month anti-IL-6 treatment whereas serum CRP levels remained undetectable and in-vitro tumor proliferation remained dependent upon IL-6<sup>[2]</sup>. The present findings did not encourage us to pursue such anti-IL-6 therapy in patients with MM using a single antibody. Alternative strategies that did not lead to accumulation of monomeric immune complexes should be developed.

The second important point is the phenomenon was due to the decrease of the anti-IL-6 mAb serum concentration to undetectable levels and ,as IL-6 was continuously produced in vivo, to the increase of the ratio of IL-6-bound mAb to free mAb. This allowed the dissociation of these immune complexes by the IL-6 receptors of the very sensitive B9 hybridoma. This again emphasizes the need to maintain a high anti-IL-6 mAb serum concentration during anti IL-treatment.

Finally, we show that this observation leads to a simple methodology for estimating the total in-vivo production of cytokines. The extent of this production has never been evaluated before. In particular, the serum level of these cytokines, when detectable, reflects only a minor part of their overall synthesis. The mathematical procedure which we developed is based on three assumptions, two of them being verified. First, the system is in steady state. As indicated above, this assumption was verified for days 40 and 60 of treatment. Second, the half-life of the IL-6/anti-IL-6 mAb complexes should be similar to that of anti - IL-6mAb. This assumption is verified for monomeric immune complexes<sup>[7]</sup>, and that was the case of the IL-6/B-E8 mAb complexes which had a 185 kDa MW. Third, there should be no route of elimination of IL-6 other than in the form of immune complexes. These assumptions were obligatory for the methodology and have possibly led us to an underestimation of the daily production of IL-6, estimated to range around 15 µg per day. It is striking that this estimate is not too far from the minimal daily dose of recombinant IL-6 known to be active in animals (1-5 µg/kg)<sup>[10-12]</sup>.

Figure 1





Figure 2





## References

- 1 Klein B, et al. ,Blood 1989;73;517
- 2 Klein B,et al. ,R. Blood 1991. 78;1198
- 3 Castell JV,et al. ,Hepatology 1990;12;1179
- 4 Wijdenes J,et al. ,Molecular Immunology 1991;28;1183
- 5 Aarden LA,et al. , Eur J Immunol 1987;17;1411
- 6 Mosmann T. J. ,Immunol Methods 1983;65;55
- 7 Plotz PH,et al. ,Molecular Immunology 1979;16;721
- 8 Konard MW,et al. ,Cancer Res1990;50;2009
- 9 Castell JV. et al. ,Eur. J. Biochem1990;189;113
- 10 Mayer P,et al. , Exp. Hematol1991;19;7
- 11 Asano s, et al. ,Blood 1990;75;1602
- 12 Takatsuki F, et al. ,Cancer Res 1990;50;2885

---

**作者简介** 陆肇阳,男,1958年生。1982年毕业于苏州医学院,1987年获硕士学位,同年分配在本院病理生理教研室,1990年赴法国攻读博士学位。从事肿瘤免疫、细胞因子在肿瘤发病机制中的作用及其临床应用的研究。